Cargando…
Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Autores principales: | Su, Shu, Hu, Bian, Shao, Jie, Shen, Bin, Du, Juan, Du, Yinan, Zhou, Jiankui, Yu, Lixia, Zhang, Lianru, Chen, Fangjun, Sha, Huizi, Cheng, Lei, Meng, Fanyan, Zou, Zhengyun, Huang, Xingxu, Liu, Baorui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244626/ https://www.ncbi.nlm.nih.gov/pubmed/28102301 http://dx.doi.org/10.1038/srep40272 |
Ejemplares similares
-
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
por: Su, Shu, et al.
Publicado: (2016) -
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019) -
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
por: Su, Shu, et al.
Publicado: (2015) -
Corrigendum: CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion
por: Ali, Zahir, et al.
Publicado: (2016) -
Corrigendum: The driving force of prophages and CRISPR-Cas system in the evolution of Cronobacter sakazakii
por: Zeng, Haiyan, et al.
Publicado: (2017)